Biomaterials and Stem Cells Offer New Hope for Spinal Cord Injury Recovery
A comprehensive review of cell-based therapies and engineered biomaterials for SCI, covering ESCs, MSCs, NSCs, and scaffold strategies.
Summary
Spinal cord injury affects millions worldwide, costing up to $4 million per patient in lifetime healthcare. This 2025 review in the Journal of Translational Medicine systematically examines preclinical and early clinical evidence for cell-based therapies — including embryonic stem cells, mesenchymal stem cells, neural stem cells, oligodendrocyte progenitor cells, Schwann cells, and olfactory ensheathing cells — combined with engineered biomaterials such as hydrogels, collagen scaffolds, polycaprolactone fibers, and 3D-printed constructs. The authors evaluate how these strategies address the hostile post-injury microenvironment, reduce glial scarring, promote axonal regeneration, and support remyelination, identifying key advantages and limitations of each approach for translating preclinical promise into clinical reality.
Detailed Summary
Spinal cord injury (SCI) remains one of the most devastating neurological conditions, with global prevalence ranging from 25 to 1,300 per million population and approximately 1 million new cases annually. The lifetime healthcare cost per patient reaches $2–4 million USD, making SCI's socioeconomic burden second only to mental disorders among neurological diseases. Despite advances in surgical decompression, pharmacological neuroprotection (notably high-dose methylprednisolone, whose efficacy the NASCIS I/II trials found only moderate), and rehabilitation, sustained meaningful recovery remains elusive for patients with severe injuries. This comprehensive 2025 review synthesizes the rapidly growing literature — noting that publications on cell therapy for SCI grew from 273 articles between 1995–2010 to 312 in just the four years 2021–2025, with the most recent four years accounting for 28% of the total published body of work.
The review organizes SCI pathophysiology into three progressive phases. The acute phase involves vascular damage, hemorrhage, excitotoxicity, free radical formation, and ionic imbalance with release of proinflammatory cytokines including IL-1β, IL-6, and TNF-α. The subacute phase features Wallerian degeneration, acute axonal demyelination, macrophage/microglial infiltration, reactive astrogliosis, and continued ROS generation. The chronic phase is characterized by cystic cavitation, constrained axonal regeneration, restricted remyelination, and progressive glial scar consolidation — all of which create a profoundly hostile microenvironment that conventional treatments cannot adequately address.
Cell replacement therapy is reviewed across two complementary strategies: transplantation of exogenous cells and activation of endogenous progenitor populations. Embryonic stem cells (ESCs) offer pluripotency and robust differentiation potential but carry ethical constraints and teratoma risk. Mesenchymal stem cells (MSCs), sourced from bone marrow and adipose tissue, demonstrate strong immunomodulatory and paracrine trophic effects with lower immunogenicity, making them among the most clinically advanced candidates. Neural stem cells (NSCs) and oligodendrocyte progenitor cells (OPCs) show particular promise for remyelination and direct neural circuit reconstruction. Schwann cells and olfactory ensheathing cells, both naturally occurring myelinating glia, have entered early human trials with safety signals that are generally favorable, though functional gains remain modest.
The biomaterials section covers hydrogels, collagen-based scaffolds, polycaprolactone fiber constructs, and emerging 3D-printed platforms. These materials serve as physical bridges across injury cavities, provide mechanical cues mimicking the native extracellular matrix, and can be loaded with trophic factors or anti-inflammatory agents for controlled local release. The review highlights synergistic combinations — for example, MSCs seeded into hydrogel scaffolds — that simultaneously address multiple barriers: cell survival at the transplant site, directed differentiation, and modulation of the inflammatory cascade. Induced pluripotent stem cells (iPSCs) and reprogrammed cells such as adipocyte-derived dedifferentiated fat cells are also discussed as emerging autologous strategies that circumvent immune rejection.
The authors conclude that no single approach is sufficient. The optimal strategy likely involves a precisely timed, multimodal combination of biomaterial scaffolding, appropriate cell type selection based on injury phase, neurotrophic factor supplementation, and rehabilitation. Key translational bottlenecks include poor graft survival in the hostile post-injury niche, risk of tumor formation with pluripotent cells, the need for large-animal model validation before human trials, and the absence of standardized outcome measures across studies. The rapid growth in reviews — from 95 during 1995–2010 to 243 during 2021–2025 — reflects both the field's momentum and the continuing gap between preclinical promise and clinical translation.
Key Findings
- SCI affects 25–1,300 per million globally with ~1 million new cases/year; lifetime healthcare cost reaches $2–4 million USD per patient
- Publications on cell therapy for SCI grew from 273 articles (1995–2010) to 312 in just the four years 2021–2025, with reviews increasing from 95 to 243 in the same periods
- The most recent 4 years (2021–2025) account for 28% of all published cell therapy/SCI literature, signaling accelerating research momentum
- High-dose methylprednisolone (NASCIS I/II) demonstrated only moderate to modest efficacy while carrying risk of significant complications, underscoring the need for cellular and biomaterial alternatives
- MSCs from bone marrow and adipose tissue show strong immunomodulatory and paracrine trophic effects with lower immunogenicity, placing them among the most clinically advanced cell therapy candidates
- 3D-printed biomaterial scaffolds loaded with trophic factors can simultaneously bridge injury cavities, support cell survival, and deliver localized anti-inflammatory agents — addressing multiple SCI barriers at once
- Synergistic combinations of hydrogel scaffolds seeded with cells (e.g., MSCs in collagen hydrogels) outperform either biomaterial or cell therapy alone in preclinical models of axonal regeneration and glial scar reduction
Methodology
This is a comprehensive narrative review article, not a primary clinical trial or meta-analysis. The authors systematically searched and synthesized preclinical and clinical literature on cell-based therapies and biomaterials for SCI published from 1995 to 2025, with publication trend analysis conducted via database query. No specific statistical pooling, effect-size calculations, or PRISMA methodology was reported, as is typical of narrative reviews. Evidence quality ranges from rodent contusion/transection models through early-phase human safety trials.
Study Limitations
As a narrative review, this paper does not perform meta-analytic statistical pooling, so effect size comparisons across studies are qualitative rather than quantitative. Most referenced preclinical successes derive from rodent models, and the authors acknowledge that large-animal validation and standardized outcome measures remain critical unmet needs before broad clinical translation. The review is funded by the Hong Kong General Research Fund; no specific conflicts of interest are declared, but the affiliation with biomaterials chemistry departments may introduce selection bias toward biomaterial-focused approaches.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.